APC401

APC401 is a small molecule sodium channel blocker under development by Andros Pharmaceuticals for the management of perioperative and postoperative pain. It is formulated as a specialized topical emulsified solution designed for local administration at surgical sites. The drug's mechanism of action involves the modulation or blockade of voltage-gated sodium channels, which inhibits nerve conduction and reduces pain signaling in the immediate vicinity of the procedure. By utilizing a topical formulation, APC401 aims to provide localized anesthesia and analgesia while minimizing the systemic exposure and associated side effects often seen with systemic pain medications. It is currently in the preclinical stage of development.